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Objective: To evaluate epratuzumab treatment in patients with moderately-
to-severely active SLE in two international, randomized, controlled trials
(ALLEVIATE-1 and -2) and an open-label extension study (SL0006). Methods:
Ninety ALLEVIATE patients (43% BILAG A, median BILAG score 12.0) received
standard of care plus 10 total doses of placebo (n = 37) or 360 mg/m<sup>2</
sup> (n = 42) or 720 mg/m<sup>2</sup> (n = 11) epratuzumab, administered
across 12-week cycles for up to 48 weeks, with BILAG assessments every 4
weeks. Patients were followed for ≥6 months and their data combined for analysis.
The primary endpoint was BILAG response at week 12 (all BILAG A scores
reduced to B/C/D and B scores to C/D, no new A and &lt;2 new B scores).
Twenty-nine patients continued in SL0006, receiving 12-week cycles of 360 mg/
m<sup>2</sup> epratuzumab; this interim analysis was performed at median
120 weeks (range 13184) of exposure. Results: Both ALLEVIATE trials were
discontinued prematurely becau...
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Abstract
Objective. To evaluate epratuzumab treatment in patients with moderately-to-severely active SLE in two
international, randomized, controlled trials (ALLEVIATE-1 and -2) and an open-label extension study
(SL0006).
Methods. Ninety ALLEVIATE patients (43% BILAG A, median BILAG score 12.0) received standard of care
plus 10 total doses of placebo (n= 37) or 360 mg/m2 (n= 42) or 720 mg/m2 (n= 11) epratuzumab, admin-
istered across 12-week cycles for up to 48 weeks, with BILAG assessments every 4 weeks. Patients were
followed for 56 months and their data combined for analysis. The primary endpoint was BILAG response
at week 12 (all BILAG A scores reduced to B/C/D and B scores to C/D, no new A and <2 new B scores).
Twenty-nine patients continued in SL0006, receiving 12-week cycles of 360 mg/m2 epratuzumab; this
interim analysis was performed at median 120 weeks (range 13184) of exposure.
Results. Both ALLEVIATE trials were discontinued prematurely because of interruption in drug supply.
Exploratory pooled analyses found that responses at week 12 were 15/34 (44.1%) and 2/10 (20.0%) for
epratuzumab 360 and 720 mg/m2, respectively, vs 9/30 (30.0%) for placebo. Total BILAG scores were
lower in both epratuzumab arms vs placebo at week 48 and at all but two time points. The incidence of
adverse events was similar between groups. In SL0006, median total BILAG score was 8.0 (n= 29) at
study entry and 7.0 (n= 19) at week 100, with no additional safety signals.
Conclusion. This initial efficacy and safety profile of epratuzumab supports its continued development
for SLE treatment.
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Introduction
SLE is a relapsing, remitting, heterogeneous autoimmune
disease involving multiple organ systems [1, 2]. Current
SLE regimens incorporate NSAIDs, corticosteroids,
antimalarials and immunosuppressive agents, which
have the potential for multiple and serious adverse effects
[3]. The development of new treatments has been ham-
pered by the complexity of SLE and the heterogeneity of
the patient population [48].
B cells are considered to have a central role in the
pathogenesis of SLE [912] and may either promote or
inhibit the autoimmune response [13]. Biological agents
have been designed to eliminate B cells, either through
direct killing (anti-CD20 antibodies such as rituximab)
or inhibition of survival (anti-BLyS/BAFF agents such as
belimumab) [1315]. Despite positive results in small,
open-label studies, the primary endpoints were not met
in two phase III trials of rituximab [16, 17]. Belimumab
significantly improved SLE disease activity and severe
flares and has been approved for SLE treatment in the
USA and Europe [18, 19].
CD22 is a 135-kDa transmembrane sialoglycoprotein
expressed on most mature B-cell lineages and a known
regulator of B-cell activation and migration [20, 21].
Epratuzumab, the first potential SLE treatment to target
CD22, is a humanized monoclonal antibody containing the
complementarity-determining regions of the murine
monoclonal antibody mLL2 (formerly EPB-2) grafted
onto a human IgG1 genetic backbone [22].
Initial evidence of the clinical effect of epratuzumab
in SLE patients comes from a small, open-label
study. There were few significant adverse events
(AEs) and no evidence of immunogenicity [23]. Two
similar, international, multicentre randomized controlled
trials (RCTs) [ALLEVIATE-1 (SL0003; NCT00111306)
and ALLEVIATE-2 (SL0004; NCT00383214)] were
initiated in larger numbers of patients with BILAG A
and BILAG B disease activity, respectively [24, 25],
but were prematurely discontinued owing to interrup-
tion of drug supply. Available data were pooled and
subjected to exploratory analysis. In addition, patients
at US sites who had participated in either ALLEVIATE
trial were considered for inclusion in an open-label,
ongoing, long-term study (SL0006; NCT00383513).
This article reports efficacy and safety results from
the ALLEVIATE studies and SL0006. A separate
manuscript has been submitted summarizing the re-
sults of health-related quality of life and corticosteroid
use Strand et al. submitted for publication.
Patients and methods
The ALLEVIATE and SL0006 trials were conducted in
accordance with the International Conference on
Harmonization E6 Note for Guidance on Good Clinical
Practice (CPMP/ICH/135/95). Informed consents,
reviewed and approved by independent ethics commit-
tees or institutional review boards from all sites, were
signed by all patients.
ALLEVIATE RCTs
Patients
Patients were aged 518 years, with ANA titre 51:40
(measured by enzyme immunoassay with indirect fluores-
cent antibody confirmation for pattern) and54 of the ACR
revised classification criteria [26].
Patients in ALLEVIATE-1 had BILAG A disease activity
in 51 body/organ system, excluding renal or central
neurological systems [24, 25]. Patients in ALLEVIATE-2
had BILAG B activity in 52 body/organ systems [24, 25]
and had received oral corticosteroids (prednisone
520 mg/day or equivalent) at stable levels for 54
weeks before study entry. Patients on immunosuppres-
sives or antimalarials had to have been receiving them
for58 or512 weeks, respectively, with stable dose regi-
mens for 54 weeks before study entry.
Patients were excluded for pregnancy, previous
B-cell-targeted therapy, prior malignancy, active infection,
allergy to murine or human antibodies, receipt of experi-
mental therapy or any therapy with human or murine anti-
bodies within 3 months, thrombosis, spontaneous or
induced abortion, stillbirth or live birth within 4 weeks,
or antiphospholipid antibodies plus a history of thrombo-
embolic events. For ALLEVIATE-2, patients were also
excluded if they had any BILAG A score.
Study design and treatment
The ALLEVIATE trials were international, multicentre,
48-week RCTs with almost identical designs with regard
to visit intervals, treatment cycle dosing schedules
and scheduled assessments. ALLEVIATE-1 was con-
ducted at 16 sites in six countries (Belgium, Hungary,
The Netherlands, Spain, UK and USA) and ALLEVIATE-2
at 28 sites in six countries (Belgium, Italy, The
Netherlands, Spain, UK and USA). Patients in
ALLEVIATE-1 were randomized to either individualized
standard of care (SOC) plus repeated administrations of
360 or 720 mg/m2 epratuzumab or individualized SOC
plus placebo (1:1:1). Patients in ALLEVIATE-2 were ran-
domized to SOC plus repeated administrations of epratu-
zumab 360 mg/m2 or individualized SOC plus placebo
(1:1). In both studies, epratuzumab or placebo was admin-
istered intravenously in 12-week cycles for up to 48 weeks
(four infusions, at weeks 0, 1, 2 and 3, for cycle 1; two
infusions, at weeks 0 and 1, for subsequent cycles), total-
ling 10 doses.
At study entry, patients began a protocol-prescribed
corticosteroid regimen, but continued antimalarials or
other baseline immunosuppressants unchanged.
ALLEVIATE-1 patients received a flare regimen of oral or
IV corticosteroids (1 g methylprednisolone, 150 mg dexa-
methasone or equivalent) administered three times in <1
week, followed by oral corticosteroids. Oral corticosteroid
dose was selected on an individual patient basis
(0.50.8 mg/kg/day prednisone or equivalent, not exceed-
ing 60 mg/day). In ALLEVIATE-2, patients increased their
oral corticosteroid dosage by 10 mg/day prednisone (or
equivalent), maintained for at least 4 weeks. The tapering
goal in ALLEVIATE-1 was 7.510 mg/day prednisone
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(or equivalent) by weeks 20 and 24; the goal in
ALLEVIATE-2 was 57.5 mg/day prednisone (or equiva-
lent) at the same time points.
Recruitment started in Spring 2005. Dosing and enrol-
ment in both trials were prematurely discontinued on
1 September 2006, owing to interruption of drug supply.
Patients were followed for 56 months, and data from
both RCTs were combined for analysis.
Efficacy endpoints
BILAG disease activity was measured every 4 weeks and
centrally graded by an independent, blinded reviewer [24,
25]. The original primary efficacy endpoint in both studies
was week 24 three-category patient response. However,
because few patients had been treated for 24 weeks at
discontinuation and the original endpoint was unlikely to
be met within 12 weeks, this endpoint was revised within
the statistical analysis plan before unblinding. The revised
primary endpoint was BILAG response with no treatment
failure at week 12. BILAG response was defined as fol-
lows: all BILAG A scores at entry reduced to B or lower or
both BILAG B scores at entry reduced to C or lower, with
no new BILAG A and <2 new BILAG B scores in other
body/organ systems. Treatment failure was defined as
new or increased use of oral corticosteroids or other
immunosuppressants above baseline.
Secondary efficacy endpoints included the following:
BILAG responses at weeks 24 and 36; time to initial
BILAG response; total BILAG score at weeks 12, 24 and
48 (BILAG A = 9, BILAG B = 3, BILAG C = 1, BILAG D/E = 0)
[27] and time to first sustained BILAG response (over 52
consecutive visits).
Safety and laboratory endpoints
AEs were coded according to the Medical Dictionary for
Regulatory Activities (MedDRA), Version 8.0. Their severity
was assessed using the National Cancer Institute
Common Terminology Criteria for Adverse Events (NCI
CTCAE), Version 3.0, where possible. The following
safety endpoints were evaluated: incidence of AEs,
including infusion-related AEs and serious AEs (SAEs);
incidence of infections; immunogenicity by human
anti-human antibody (HAHA), specifically anti-
epratuzumab antibody titres; and vital sign measure-
ments. Serum biochemistry, haematological parameters
and urinalysis results were also evaluated. Serum im-
munoglobulins (IgA, IgG and IgM) and circulating B- and
T-cell levels were measured at screening, at weeks 4 and
12 following each infusion and at early termination.
Statistical analyses
The base population for all analyses was the intention to
treat (ITT) (all randomized patients) population. Values for
individual time points for members of that population were
calculated using an observed case (including only sub-
jects with a non-missing value) analysis. All analyses
used a two-sided hypothesis test at the overall 5% level
of significance but were exploratory and not adjusted for
multiple testing. Hence, P values and other statistical tests
are of limited validity and should be interpreted cautiously.
The null hypothesis for the primary efficacy analysis
was that the proportion of responders would be equal
among patients receiving 360 mg/m2 epratuzumab,
720 mg/m2 epratuzumab or placebo. The analysis used
a CochranMantelHaenszel test, stratified by ethnicity
(Caucasian vs non-Caucasian), baseline immunosuppres-
sive medications (used vs not used) and corticosteroid
flare regimen (oral vs i.v. vs none). The originally planned
sample sizes were not achieved—36 vs 510 (7%) for
ALLEVIATE-1; 54 vs 300 (18%) for ALLEVIATE-2—and al-
though the patient groups were combined, the combined
analysis remains underpowered to detect differences.
Statistical analyses were also carried out for some sec-
ondary endpoints. Differences in total BILAG score be-
tween treatment groups were assessed using analysis of
covariance with effects for treatment group, ethnicity,
baseline immunosuppressant use, corticosteroid flare
regimen and baseline total BILAG score.
SL0006 open-label extension study
All ALLEVIATE patients at US sites were eligible for enrol-
ment in SL0006, if in the investigator’s judgment, the pa-
tient had benefited from randomized treatment, and there
were no safety concerns that precluded receiving epratu-
zumab. The primary objective was to assess the long-term
safety and efficacy of epratuzumab 360 mg/m2. All pa-
tients were assigned to receive this dose in 12-week
maintenance cycles (two infusions, on weeks 0 and 1 of
each cycle). Because of interruption of drug supply, there
was a median delay of 165 days (range 1400) between
completion of the ALLEVIATE studies and entry into
SL0006. Safety and efficacy assessments in SL0006
were similar to those in the ALLEVIATE RCTs, performed
every 4 weeks. An interim analysis was conducted to
obtain preliminary long-term safety and efficacy data.
The cutoff for these analyses was 31 December 2009,
representing a median 120 weeks (range 13184) of
exposure.
Results
ALLEVIATE RCTs
Patient characteristics
Ninety patients were randomized in the ALLEVIATE RCTs:
36 in ALLEVIATE-1 and 54 in ALLEVIATE-2 (Fig. 1).
Baseline demographics are shown in Tables 1 and 2.
Patients had high disease activity overall and as antici-
pated, given the differing entry criteria for ALLEVIATE-1
and ALLEVIATE-2, patients receiving epratuzumab
720 mg/m2 had higher disease activity than those receiv-
ing epratuzumab 360 mg/m2. Although most baseline
demographics were largely comparable between treat-
ment groups, some differences were observed between
the 720 mg/m2 group vs the placebo and epratuzumab
360 mg/m2 groups, such as the nature of body systems
affected (fewer patients in the 720 mg/m2 group had
mucocutaneous system involvement) and distribution of
ethnic groups (more patients in the 720 mg/m2 group
were of African descent). In addition, median (range)
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FIG. 1 Patient disposition (ITT population) through ALLEVIATE and SL0006.
Patients who continued to week 12 received a total of 4 infusions (1 treatment cycle); patients who continued to week 24
received a total of 8 infusions (2 treatment cycles) and patients who continued to week 48 received a total of 12 infusions
(3 treatment cycles). *Two patients were randomized but did not receive epratuzumab.
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baseline steroid use was higher in the epratuzumab
720 mg/m2 group [46.0 (10.080.0) mg/day] than in the
placebo and epratuzumab 360 mg/m2 groups [20.0
(15.060.0) mg/day and 25.0 (10.060.0) mg/day, respect-
ively]. Patients who had received one cycle of therapy
between weeks 0 and 3 (four infusions) were evaluated
at week 12 (n= 74). Similarly, 33 patients who received
three cycles of therapy were evaluated at week 48
(Fig. 1). Placebo groups from both studies were combined
for analysis.
Efficacy
Beginning at week 4 and continuing through week 48,
total BILAG scores in the epratuzumab treatment arms
remained numerically lower than placebo at all but two
time points (Fig. 2A). The median time to initial BILAG
response was shorter in both epratuzumab arms [median
57.0 (95% CI 38.0, 93.0) days in the 360 mg/m2 arm and
39.0 (35.084.0) days in the 720 mg/m2 arm] than in the
placebo arm [median 93.0 (40.0120.0) days], but did not
achieve significance [hazard ratio (HR) 1.19 and 1.21,
TABLE 1 Patient demographics at baseline in the ALLEVIATE studies and at study entry into SL0006
Pooled data from ALLEVIATE-1 and ALLEVIATE-2 SL0006
Placebo (n= 37)
Epratuzumab
360 mg/m2 (n= 42)
Epratuzumab
720 mg/m2 (n= 11)
Epratuzumab
360 mg/m2 (n= 29)
Age (years), median (range) 38.0 (1858) 39.0 (2059) 38.0 (2152) 39.0 (2261)
Gender
Male 3 (8.1) 1 (2.4) 1 (9.1) 3 (10.3)
Female 34 (91.9) 41 (97.6) 10 (90.9) 26 (89.7)
Ethnicity
Caucasian 25 (67.6) 27 (64.3) 7 (63.6) 23 (79.3)
Black 8 (21.6) 7 (16.7) 3 (27.3) 3 (10.3)
Asian 1 (2.7) 4 (9.5) 1 (9.1) 2 (6.9)
Other 3 (8.1) 4 (9.5) 0 (0.0) 1 (3.4)
Median total BILAG scorea (range) 12.0 (726) 12.0 (626) 15.0 (1034) 11.0 (821)
Median total SLEDAI score (range) 12.0 (432) 10.0 (018) 8.0 (414) N/A
No. of patients with 51 BILAG A 13 (35) 15 (35.7) 11 (100) 10 (34.5)
Use of immunosuppressive(s) 24 (64.9) 28 (66.7) 5 (45.5) 29 (100)
Prednisone equivalent dose (mg/day)
47.5 0 2 (4.8) 0 17 (58.6)
>7.515 3 (8.1) 1 (2.4) 2 (18.2) 9 (31.0)
>1525 21 (56.8) 21 (50.0) 1 (9.1) 2 (6.9)
>25 13 (35.1) 18 (42.9) 8 (72.7) 1 (3.5)
Data as n (%) unless specified otherwise. N/A: not measured. aThe total BILAG score is calculated as the sum of eight organs/
systems where categories AE are converted into numerical scores (A = 9, B = 3, C = 1, D = 0, E = 0) [27].
TABLE 2 Number (%) of patients with BILAG A or B scores for each body system at baseline in the ALLEVIATE studies
and at study entry into SL0006
Pooled data from ALLEVIATE-1 and ALLEVIATE-2 SL0006
Placebo (n= 37)
Epratuzumab
360 mg/m2 (n= 42)
Epratuzumab
720 mg/m2 (n= 11)
Epratuzumab
360 mg/m2 (n= 29)
Body system A B A B A B A B
General 0 (0) 11 (30) 1 (2) 16 (38) 1 (9) 3 (27) 0 (0) 14 (48)
Mucocutaneous 5 (14) 26 (70) 10 (24) 26 (62) 3 (27) 3 (27) 5 (17) 19 (66)
Neurological 0 (0) 1 (3) 0 (0) 2 (5) 1 (9) 0 (0) 1 (3) 3 (10)
Musculoskeletal 5 (14) 24 (65) 4 (10) 29 (69) 6 (55) 3 (27) 2 (7) 23 (79)
CV and respiratory 1 (8) 6 (16) 2 (5) 3 (7) 1 (9) 1 (9) 2 (7) 2 (7)
Vasculitis 2 (5) 7 (19) 0 (0) 5 (12) 1 (9) 1 (9) 0 (0) 4 (14)
Renal 1 (3) 5 (14) 0 (0) 4 (10) 0 (0) 1 (9) 0 (0) 1 (3)
Haematological 1 (3) 3 (8) 0 (0) 7 (17) 0 (0) 1 (9) 0 (0) 1 (3)
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respectively]. The median time to first sustained BILAG
response was 93.0 days (HR 2.18; 95% CI 1.12, 4.24;
P= 0.021 vs placebo) for patients receiving epratuzumab
360 mg/m2 and 84.0 days (HR 1.21; 95% CI 0.46, 3.16;
P= 0.704 vs placebo) for patients receiving epratuzumab
720 mg/m2 (Fig. 2B).
Among the 74 patients receiving 12 weeks of treatment,
the percentage of responders was higher in the epratuzu-
mab 360 mg/m2 arm (44.1%, 15/34) than in the 720 mg/m2
(20.0%, 2/10) or placebo (30.0%, 9/30) arms, although
these differences were not statistically significant
(P= 0.177). Among patients from ALLEVIATE-1, week 12
BILAG response was 63.6% (7/11) in the 360 mg/m2 arm,
20.0% (2/10) in the 720 mg/m2 arm and 30.0% (3/10) in
the placebo arm. Among patients from ALLEVIATE-2,
week 12 BILAG response was 34.8% (8/23) in the
360 mg/m2 arm and 30.0% (6/20) in the placebo arm.
A total of 62 and 46 patients reached weeks 24 and 36,
respectively. At week 24, the percentage of responders
was also higher with epratuzumab 360 mg/m2 (34.4%,
11/32) than 720 mg/m2 (28.6%, 2/7) or placebo (17.4%,
4/23; P= 0.165 and P= 0.375, respectively). At week 36,
there was no treatment advantage for the epratuzumab
360 mg/m2 treatment group over placebo.
At week 48, median (range) total numerical BILAG
scores in patients treated with 360 mg/m2 (n= 14) and
720 mg/m2 (n= 5) epratuzumab were reduced from
12 (626) and 15 (1034), respectively, at baseline to
4 (214) and 6 (115). Placebo-treated patients on indivi-
dualized SOC background (n= 14) had reductions from
12 (726) at baseline to 7.5 (316), yielding a treatment
advantage for epratuzumab 360 mg/m2 over placebo of
3.9 points (least-squares mean change, 95% CI 0.6, 7.2;
P= 0.024). The change from baseline in total BILAG score
FIG. 2 Total BILAG scores and time to first sustained BILAG response in the ALLEVIATE studies.
(A) Median total BILAG scores at each time point in the ALLEVIATE studies for patients receiving epratuzumab
360 mg/m2, epratuzumab 720 mg/m2 or placebo. Numbers shown below graph are number of patients evaluable at each
time point (overall treatment effect P= 0.028). (B) Time to first sustained BILAG response (ITT population; 360 mg/m2
P= 0.021 vs placebo, 720 mg/m2 P= 0.704 vs placebo). *P= 0.024 for 360 mg/m2 epratuzumab vs placebo at week 48.
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for all patients receiving epratuzumab vs placebo at
week 48 was also significant (P= 0.028).
Median (range) corticosteroid dose was lower at
week 24 than at baseline in all three arms: 9.64 (0137.4)
mg/day in the placebo arm, 10.55 (024.6) mg/day in the
360 mg/m2 arm and 13.51 (4.349.0) mg/day in the
720 mg/m2 arm. Detailed analysis of corticosteroid use
during the ALLEVIATE studies has been presented as an
abstract and is discussed in a separate article Strand et al.
submitted for publication [28].
Adverse events
The safety population included 88 treated patients (two
randomized patients were not treated owing to withdrawn
consent or clinical hold) of whom 51 received either
360 mg/m2 (n= 40) or 720 mg/m2 (n= 11) epratuzumab.
Median (range) epratuzumab exposure was 2920
(14137191) mg and 4341 (21037360) mg for the 360
and 720 mg/m2 arms, respectively. The incidences of
AEs, SAEs and infusion-related AEs were similar in the
epratuzumab and placebo groups (Table 3). Assessment
of vital signs (pulse rate, blood pressure, respiratory
rate, temperature and body weight) did not reveal clinical
concerns. All infusion events were mild or moderate by NCI
CTCAE grading (Version 3.0) and the overall incidence was
similar between epratuzumab and placebo groups.
One patient who received 720 mg/m2 epratuzumab died
of a cerebral haemorrhage 16 weeks after the last dose
of study medication. This patient had a prior history of
seizure disorder resulting from an occipital infarction and
had been hospitalized after completion of this study as a
result of acute respiratory distress due to a pneumococcal
TABLE 3 Number (%) of patients with AEs in the ALLEVIATE safety population (all patients who received study
medication) and SL0006
ALLEVIATE populationa SL0006b
Placebo (n= 37)
Epratuzumab
360 mg/m2 (n= 40)c
Epratuzumab
720 mg/m2 (n= 11)
Epratuzumab
360 mg/m2 (n= 29)
All AEs 34 (92) 36 (90) 11 (100) 29 (100)
Infusion-related AEs 7 (19) 7 (18) 2 (18) 6 (21)
Serious AEs 11 (30) 10 (25) 4 (36) 10 (35)
Infections (51) 26 (70) 28 (70) 7 (64) 26 (90)
Serious infectionsd 8 (22) 5 (12) 4 (36) 3 (10)
AEs leading to discontinuation 3 (8) 0 (0) 3 (27) 3 (10)
Deaths 0 (0) 0 (0) 1 (9) 0 (0)
AEs 510 incidence
Conjunctivitis 2 (5) 1 (3) 2 (18) 3 (10)
Upper respiratory tract infection 13 (35) 8 (20) 3 (27) 13 (45)
Urinary tract infection 6 (16) 6 (15) 2 (18) 8 (28)
Diarrhoea 9 (24) 7 (18) 3 (27) 8 (28)
Headache 6 (16) 6 (15) 6 (55) 6 (21)
Migraine 1 (3) 1 (3) 2 (18) 4 (14)
Nasopharyngitis 4 (11) 4 (10) 0 (0) 10 (34)
Arthralgia 4 (11) 9 (23) 3 (27) 1 (3)
Nausea 5 (14) 5 (13) 3 (27) 7 (24)
Bronchitis 2 (5) 4 (10) 0 (0) 7 (24)
Dizziness 4 (11) 4 (10) 0 (0) 3 (10)
Pyrexia 3 (8) 5 (13) 2 (18) 3 (10)
Sinusitis 0 (0) 5 (13) 1 (9) 9 (31)
Abdominal pain 3 (8) 4 (10) 2 (18) 9 (31)
Oral candidiasis 2 (5) 6 (15) 1 (9) 2 (7)
Peripheral oedema 2 (5) 4 (10) 2 (18) 2 (7)
SLEe 2 (5) 4 (10) 0 (0) 4 (14)
Pharyngo-laryngeal pain 2 (5) 4 (10) 1 (9) 3 (10)
Chest pain 1 (3) 5 (13) 1 (9) 3 (10)
Cough 0 (0) 4 (10) 2 (18) 3 (10)
Blurred vision 0 (0) 4 (10) 0 (0) 0 (0)
aDuration of exposure in ALLEVIATE-1 and ALLEVIATE-2 varied between patients. bIncidence of events was not corrected
for duration of exposure in SL0006. cSafety analyses exclude 2 of the 42 patients assigned to this treatment arm who did
not receive any epratuzumab. dSerious infection: life-threatening, required hospitalization or prolongation of existing hospital-
ization. eAEs that could potentially reflect symptoms of active SLE disease that were experienced by 5 or more patients in the
active treatment groups were arthralgia, myalgia, SLE, pyrexia (if not related to infusion), rash (if not related to infusion), joint
effusion and headache. Although these were experienced by a slightly higher percentage of patients in the 360 mg/m2 treat-
ment group, the relatively low number of patients experiencing these events makes it difficult to draw conclusions.
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infection of the larynx. The day after this infection
resolved, the patient experienced acute hypertension
and headache and died 2 h after onset of symptoms.
Of 51 patients receiving epratuzumab, all serum sam-
ples were negative for HAHA except for two patients
who developed low-level titres (maximum, 690 ng/ml) of
uncertain significance with no clinical sequelae nor
changes in laboratory safety parameters.
Haematological and immunological parameters
At week 12, median B-cell levels were lower than at
baseline by 31% and 52% in the 360 and 720 mg/m2
groups, respectively, compared with 9.1% in the placebo
arm. Median B-cell levels continued to be lower in the
treatment arms than in the placebo arm through
to week 48 (supplementary Fig. 1a, available at
Rheumatology Online). Statistical testing was not carried
out on these data. T-cell levels remained stable in all
treatment groups (supplementary Fig. 1b, available at
Rheumatology Online). The median percentage changes
from baseline in IgG and IgA levels were similar across
treatment groups in ALLEVIATE-1 and -2 (supplementary
Fig. 2, available at Rheumatology Online).
SL0006 open-label extension study
A total of 29 patients were enrolled in SL0006 (10 from
ALLEVIATE-1 and 19 from ALLEVIATE-2). All received
epratuzumab 360 mg/m2 (Fig. 1). At the cutoff for the effi-
cacy and safety analyses, the median (range) treatment
duration was 120 weeks (13184, n= 29). Median (range)
total BILAG score was 8.0 (321, n= 29) at study entry
and 7.0 (311, n= 19) at week 100. One patient discon-
tinued because of lack of efficacy. Changes in BILAG
disease activity for individual body systems during
SL0006 are shown in Table 4; most instances of BILAG
A/B at SL0006 visit 1 improved to BILAG C/D during the
study.
All patients reported at least one AE, with 10 patients
(35%) experiencing at least one SAE and 3 (10%)
discontinuing because of AEs (Table 3). After adjusting
for duration of exposure, the highest rates of AE were
for nasopharyngitis, sinusitis, upper respiratory tract infec-
tion and urinary tract infection. Infusion-related AEs were
reported in 6 (21%) patients in SL0006, corresponding
to an infusion-related AE rate of 10.8 per 100 years of
exposure. Serious infections were reported in 3 (10%)
patients and included pneumonia, pyelonephritis and
urinary tract infection.
B-cell and T-cell levels remained stable over the 2 years
of data from SL0006 included for this evaluation (supple-
mentary Fig. 3, available at Rheumatology Online).
No statistical testing was performed on these results.
Immunoglobulin responses followed a similar pattern to
the two ALLEVIATE trials (supplementary Fig. 4, available
at Rheumatology Online). All laboratory parameters con-
tinue to be monitored in the study follow-up.
Discussion
The original primary endpoint for the ALLEVIATE studies
could not be evaluated as intended. However, despite
being underpowered, some of the exploratory analyses
performed here provide support for the hypothesis that
treatment of SLE with 360 mg/m2 epratuzumab plus
SOC and corticosteroids may be effective at reducing
SLE disease activity. In addition, epratuzumab plus SOC
showed a safety profile similar to placebo plus SOC.
Based on BILAG and SLEDAI scores at baseline, this
patient population had high initial disease activity com-
pared with other recent SLE trials [18, 19]. In addition,
patients receiving epratuzumab 720 mg/m2 were small in
number, n= 11, as well as having higher disease activity
with more corticosteroid and antimalarial therapies than
the other groups. This may partly explain why, despite
higher response rates with 360 mg/m2 epratuzumab, over-
all treatment response (both epratuzumab dosing groups
combined) at weeks 12 and 24 were not statistically sig-
nificantly different from the placebo group. Evidence of
treatment effect based on total BILAG scores did not
achieve statistical significance except at week 48.
TABLE 4 Changes in BILAG disease activity system scores during SL0006
Baseline C/D/E scores Baseline A/B scores
n A/B grade during studya n C/D grade during study
General 21 7 (33.3%) 8 8 (100.0%)
Mucocutaneous 12 9 (75.0%) 17 15 (88.2%)
Neurological 27 8 (29.6%) 2 2 (100.0%)
Musculoskeletal 15 10 (66.7%) 14 14 (100.0%)
CV and respiratory 27 8 (29.6%) 2 2 (100.0%)
Vasculitis 28 2 (7.1%) 1 1 (100.0%)
Renal 27 9 (33.3%) 2 2 (100.0%)
Haematological 27 5 (18.5%) 2 1 (50.0%)
This table shows patients with BILAG C/D/E at baseline that worsened to A/B and patients with BILAG A/B at baseline that
improved to C/D. aOnly two BILAG As occurred during the study, one in the general category and the other in the neurological
category.
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These results are consistent with the first clinical trial
of epratuzumab in SLE, a small, single-centre, single-
arm, open-label study in which epratuzumab was admin-
istered at 360 mg/m2 every other week for a total of
four doses, and a statistically significant improvement
in total BILAG scores was observed up to 32 weeks
after study initiation [23]. Differences in clinical responses
between the two epratuzumab dose groups are consist-
ent with the pattern seen in EMBLEM (NCT00624351),
a phase IIB study of epratuzumab with five active arms,
initiated in 2008. In that study, responses at week 12
were greater in patients receiving total epratuzumab
doses of 2400 mg than in those receiving total doses of
1200 and 1800 mg, and greater than in those receiving
3600 mg [29].
Analyses of safety endpoints did not identify any add-
itional signals compared with the anticipated risks in an
SLE population, and there were no apparent dose-related
toxicities. The larger proportion of patients in the placebo
group experiencing upper respiratory tract infections
(35% vs 22%) may reflect higher corticosteroid dosing in
this group compared with the epratuzumab treatment
groups and merits further investigation. The incidence of
AEs leading to discontinuation of study medication was
similar across treatment groups: three patients each in the
placebo and 720 mg/m2 epratuzumab arms. No patient in
the 360 mg/m2 epratuzumab arm discontinued for safety
reasons. In addition, no new or unexpected AEs were
observed while total numerical BILAG scores were main-
tained during approximately 2 years of continued expos-
ure in SL0006. HRQOL changes and corticosteroid use
during the ALLEVIATE studies are described in a separate
report (Strand et al. submitted for publication).
The limitations of our conclusions must be acknowl-
edged. The analyses were designed before unblinding
but are based on data pooled from two interrupted
RCTs with differences in disease activity between treat-
ment groups and in which the original planned sample
sizes were not achieved. Even the pooled analysis was
underpowered to detect clinically relevant differences be-
tween treatment groups and may also be subject to sur-
vivorship bias at later time points. The follow-up data in
SL0006 also are complicated by the variable treatment
duration and the delay between ALLEVIATE and SL0006
due to interruption of study drug supply.
Finally, while the mechanism of action of epratuzumab
is not yet fully defined, treatment leads to selective modu-
lation of B-cell activation and induces changes in B-cell
migration [23, 30, 31]. These changes in migration are
consistent with the observation that CD27 B cells are
preferentially reduced in the peripheral blood during epra-
tuzumab treatment [31]. In the ALLEVIATE RCTs, median
B-cell counts were partially reduced from baseline (about
50% reduction) in both active treatment groups, while
T-cell levels remained stable. This suggests that epratu-
zumab may have a complex immunomodulatory effect on
B-cell activity.
These exploratory analyses of the efficacy and safety
profile of epratuzumab over a substantial follow-up period
support its continued development for the treatment of
patients with moderately-to-severely active SLE. RCTs
are currently underway to confirm the efficacy of epratu-
zumab in this patient population.
Rheumatology key messages
. This exploratory pooled analysis provided evi-
dence of epratuzumab treatment effect in SLE
patients.
. The safety profile of epratuzumab plus SOC in
patients with SLE was similar to placebo plus SOC.
. This initial efficacy and safety profile of epratuzu-
mab supports its continued development for SLE
treatment.
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